Shuttle Pharmaceuticals Holdings, Inc. 8-K

What Happened
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K reporting two governance changes. On January 6, 2025 the Board appointed Yuying Liang, CPA, as Chief Financial Officer through an engagement with Yuying Liang Professional Corp. (YLPC). Concurrently, Chris Cooper will no longer serve as the Company’s Chief Financial Officer but will continue as Interim Chief Executive Officer. Separately, director Sachin Pathigoda resigned from the Board effective January 8, 2026; the resignation was not due to any disagreement with the Company.

Key Details

• Yuying Liang was appointed CFO (engagement effective Jan 6, 2025); her engagement is with Yuying Liang Professional Corp.
• YLPC will be paid a monthly fee of $15,000 USD plus applicable taxes under the Engagement Letter (Exhibit 10.1).
• Chris Cooper will remain with the company as Interim CEO but will no longer be the Principal Financial Officer.
• Director Sachin Pathigoda resigned effective January 8, 2026; the Board is seeking a successor and the resignation was not due to any disagreement.
• Filing confirms no family relationships, no special arrangements leading to the appointment, and no reportable related-party transactions for Ms. Liang.

Why It Matters
A new CFO can affect financial reporting, controls, and investor communications; the company engaged Ms. Liang via a consulting contract at a clear monthly cost ($15k), indicating a defined, outsourced CFO arrangement. Chris Cooper’s continued role as Interim CEO provides executive continuity while the Board searches for a replacement director, which could temporarily affect board composition and oversight. The filing notes no disagreements or reportable related-party transactions, which is relevant to governance and transparency.